Valo Health has secured $190M in Series B funding led by The Public Sector Pension Investment Board and Flagship Pioneering and several new institutional investors including Invus Public Equities, HBM Healthcare Investments, Atinum Investment, and Mirae Asset Capital.

Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reduce cost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.